This application claims priority under 35 U.S.C. § 119 to Korean Patent Application Nos. 10-2020-0045374, filed on Apr. 14, 2020, and 10-2021-0046891, filed on Apr. 12, 2021, in the Korean Intellectual Property Office, the contents of which are incorporated by reference herein in their entirety.
The present disclosure relates to an organometallic compound, an organic light-emitting device including the organometallic compound, and an electronic apparatus including the organic light-emitting device.
Organic light-emitting devices (OLEDs) are self-emissive devices which produce full-color images. In addition, OLEDs have wide viewing angles and exhibit excellent driving voltage and response speed characteristics.
OLEDs include an anode, a cathode, and an organic layer between the anode and the cathode and including an emission layer. A hole transport region may be between the anode and the emission layer, and an electron transport region may be between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and the electrons recombine in the emission layer to produce excitons. The excitons may transit from an excited state to a ground state, thus generating light.
Provided are an organometallic compound, an organic light-emitting device including the organometallic compound, and an electronic apparatus including the organic light-emitting device.
Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments of the disclosure.
According to an aspect of an embodiment, an organometallic compound represented by Formula 1-1 is provided.
In Formula 1-1,
M is a transition metal,
X1 is O, S, or N(R″′),
a bond between X1 and M is a covalent bond,
X2 to X4 and Y1 are each independently C or N,
one bond of a bond between X2 and M, a bond between X3 and M, and a bond between X4 and M is a covalent bond, while the remaining bonds are each be a coordinate bond,
X51 is O, S, N-[(L7)b7-(R7)c7], C(R7)(R8), Si(R7)(R8), Ge(R7)(R8), or C(═O),
Z11 is N or C-[(L11)b11-(T11)c11], Z12 is N or C-[(L12)b12-(T12)c12], Z13 is N or C-[(L13)b13-(T13)c13], and Z14 is N or C-[(L14)b14-(T14)c14],
Z21 is N or C-[(L21)b21-(T21)c21], Z22 is N or C-[(L22)b22-(T22)c22], and Z23 is N or C-[(L23)b23-(T23)c23],
Z31 is N or C-[(L31)b31-(T31)c31], Z32 is N or C-[(L32)b32-(T32)c32], and Z33 is N or C-[(L33)b33-(T33)c33],
Z41 is N or C-[(L41)b41-(T41)c41], Z42 is N or C-[(L42)b42-(T42)c42], Z43 is N or C-[(L43)b43-(T43)c43], and Z44 is N or C-[(L44)b44-(T44)c44],
L7, L11 to L14, L21 to L23, L31 to L33 and L41 to L44 are each independently a single bond, a C1-C10 alkylene group unsubstituted or substituted with at least one R10a, a C5-C30 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C30 heterocyclic group unsubstituted or substituted with at least one R10a,
b7, b11 to b14, b21 to b23, b31 to b33 and b41 to b44 are each independently 1, 2, 3, 4, or 5,
R″′, R7, R8, T11 to T14, T21 to T23, T31 to T33 and T41 to T44 are each independently hydrogen, deuterium, —F, —Cl, —Br, —I, —SF5, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q1)(Q2), —Si(Q3)(Q4)(Q5), —Ge(Q3)(Q4)(Q5), —B(Q6)(Q7), —P(═O)(Q8)(Q9), or —P(Q8)(Q9),
c7, c11 to c14, c21 to c23, c31 to c33 and c41 to c44 are each independently 1, 2, 3, 4, or 5,
wherein, the organometallic compound represented by Formula 1-1 satisfies:
1) one of Condition 11, Condition 12 and Condition 13,
2) Condition 11 and Condition 13, or
3) Condition 12 and Condition 13,
Z42 in Formula 1-1 is C-[(L42)b42-(T42)c42], Condition 11
T42 is a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, or a substituted or unsubstituted C1-C10 heterocycloalkenyl group, and
c42 is 1,
Z42 in Formula 1-1 is C-[(L42)b42-(T42)c42], Condition 12
T42 is a group represented by Formula 41, and
c42 is 1,
*—C(Q41)(Q42)(Q43) Formula 41
wherein in Formula 41,
Q41 to Q43 are each independently deuterium, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,
at least one of Q41 to Q43 are each independently a substituted or unsubstituted C2-C60 alkyl group, a substituted or unsubstituted C3-C10 cycloalkyl group, or a substituted or unsubstituted C6-C60 aryl group, and
* indicates a binding site to an adjacent atom,
X51 in Formula 1-1 is N-[(L7)b7-(R7)c7], Condition 13
L7 is a benzene group, or a naphthalene group, each unsubstituted or substituted with at least one R10a,
R7 is a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, or a substituted or unsubstituted C1-C10 heterocycloalkenyl group, and
c7 is 1,
each of i) at least two of T11 to T14, ii) at least two of T21 to T23, iii) at least two of T31 to T33, iv) at least two of T41 to T44 and v) at least two of T11 to T14, T21 to T23, T31 to T33, and T41 to T44 are optionally bound to each other to form a C5-C30 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C30 heterocyclic group unsubstituted or substituted with at least one R10a,
R10a may be understood by referring to the description of T11 provided herein,
a substituent of the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C3-C10 cycloalkyl group, the substituted C1-C10 heterocycloalkyl group, the substituted C3-C10 cycloalkenyl group, the substituted C1-C10 heterocycloalkenyl group, the substituted C6-C60 aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C1-C60 heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group is
deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group,
a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), —Ge(Q13)(Q14)(Q15), —B(Q16)(Q17), —P(═O)(Q18)(Q19), —P(Q18)(Q19), or any combination thereof,
a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C6 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), —Ge(Q23)(Q24)(Q25), —B(Q26)(Q27), —P(═O)(Q28)(Q29), —P(Q28)(Q29), or any combination thereof,
—N(Q31)(Q32), —Si(Q33)(Q34)(Q35), —Ge(Q33)(Q34)(Q35), —B(Q36)(Q37), —P(═O)(Q38)(Q39), or —P(Q38)(Q39), or
any combination thereof,
wherein Q1 to Q9, Q11 to Q19, Q21 to Q29, and Q31 to Q39 are independently hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group unsubstituted or substituted with deuterium, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group unsubstituted or substituted with deuterium, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group.
According to an aspect of another embodiment, an organic light-emitting device may include a first electrode, a second electrode, and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer and at least one of the organometallic compound.
The organometallic compound may be included in the emission layer of the organic layer, and the organometallic compound included in the emission layer may serve as a dopant.
According to an aspect of another embodiment, an electronic apparatus may include the organic light-emitting device.
The above and other aspects, features, and advantages of certain embodiments of the disclosure will be more apparent from the following description taken in conjunction with the accompanying drawings, in which
The FIGURE is a schematic cross-sectional view of an organic light-emitting device according to an exemplary embodiment.
Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.
It will be understood that when an element is referred to as being “on” another element, it can be directly on the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present
It will be understood that, although the terms “first,” “second,” “third” etc. may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer or section from another element, component, region, layer or section Thus, “a first element,” “component,” “region,” “layer” or “section” discussed below could be termed a second element, component, region, layer or section without departing from the teachings herein.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, “a,” “an,” “the,” and “at least one” do not denote a limitation of quantity, and are intended to cover both the singular and plural, unless the context clearly indicates otherwise. For example, “an element” has the same meaning as “at least one element,” unless the context clearly indicates otherwise.
“Or” means “and/or.” As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.
Furthermore, relative terms, such as “lower” or “bottom” and “upper” or “top,” may be used herein to describe one element's relationship to another element as illustrated in the Figures. It will be understood that relative terms are intended to encompass different orientations of the device in addition to the orientation depicted in the Figures For example, if the device in one of the figures is turned over, elements described as being on the “lower” side of other elements would then be oriented on “upper” sides of the other elements. The exemplary term “lower,” can therefore, encompasses both an orientation of “lower” and “upper,” depending on the particular orientation of the figure Similarly, if the device in one of the figures is turned over, elements described as “below” or “beneath” other elements would then be oriented “above” the other elements. The exemplary terms “below” or “beneath” can, therefore, encompass both an orientation of above and below.
“About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within ±30%, 20%, 10% or 5% of the stated value.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.
An organometallic compound may be represented by Formula 1-1:
wherein Formula 1-1 may be understood by referring to the description.
In an embodiment, the organometallic compound may have ΔST in a range of about 0.1 eV to about 0.2 eV.
In an embodiment, the organometallic compound may have a horizontal orientation ratio of about 85% or greater.
ΔST indicates an energy gap (an absolute value) between a singlet (S1) energy level and a triplet (T1) energy level of the organometallic compound represented by Formula 1-1. The singlet (S1) energy level and the triplet (T1) energy level of the organometallic compound may be calculated using a density functional theory (DFT). A method of measuring the singlet (S1) energy level and the triplet (T1) energy level of the organometallic compound may be understood with reference to Evaluation Example 1.
In an embodiment, the organometallic compound may have ΔST in a range of about 0.13 eV to about 0.2 eV, about 0.15 eV to about 0.2 eV or about 0.176 eV to about 0.2 eV.
In one or more embodiments, the organometallic compound may have ΔST in a range of about 0.10 eV to about 0.17 eV, about 0.12 eV to about 0.17 eV, or about 0.125 eV to about 0.16 eV.
In one or more embodiments, the organometallic compound may have a horizontal orientation ratio in a range of about 85% to about 95% or about 87% to about 95%.
In one or more embodiments, the organometallic compound may have a horizontal orientation ratio in a range of about 85% to about 100%, about 87% to about 97%, or about 88% to about 95%.
The horizontal orientation ratio of the organometallic compound, as used herein, may be a horizontal orientation ratio of a transition dipole moment of the organometallic compound. The term “horizontal orientation ratio of a transition dipole moment”, as used herein, refers to, in a film including the organometallic compound, a ratio of the organometallic compound having a transition dipole moment which is horizontal with respect to the film, relative to the total organometallic compound included in the film. A horizontal orientation ratio may be measured by preparing a film including a predetermined matrix compound (e.g., mCP) and the organometallic compound and measuring a horizontal orientation ratio of the film. For example, a method of measuring a horizontal orientation ratio of the organometallic compound may be understood by referring to Evaluation Example 2.
Since the organometallic compound has a high horizontal orientation ratio of a transition dipole moment as such, namely, a greatly oriented transition dipole moment (i.e., a large optical orientation in a horizontal direction), when the film includes the organometallic compound, it may be possible for the organometallic compound to emit a large electric field in a vertical direction with respect to the film. Since light emitted by this mechanism may pass to the outside with high efficiency (i.e., efficiency of light emitted from the organometallic compound passing to the outside in a device (e.g., an organic light-emitting device) including a film (e.g., an emission layer described herein) including the organometallic compound), an electronic device, e.g., an organic light-emitting device, employing the organometallic compound, may have excellent luminous efficiency.
In one or more embodiments, the organometallic compound may have a sublimation temperature in a range of about 200° C. to about 350° C., about 200° C. to about 340° C., or about 200° C. to about 300° C. The organometallic compound may have a molecular weight of 1,200 or less or 1100 or less. As the organometallic compound has a sublimation temperature and/or a molecular weight as described above, when forming a thin film including the organometallic compound, decomposition of the organometallic compound may be substantially prevented, thus forming a thin film showing excellent performance.
wherein, in Formula 1-1, M may be a transition metal.
For example, M may be cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au).
In an embodiment, M may be Pt, Pd, or Au.
In Formula 1-1, X1 may be O, S, or N(R″′), and a bond between X1 and M may be a covalent bond. R″′ may be understood by referring to the description of R″′ provided herein.
In some embodiments, X1 may be O or S.
In an embodiment, X1 may be O.
In Formula 1-1, X2 to X4 and Y1 may each independently be C or N.
For example, X2 and X4 may each be N, and Y1 and X3 may each be C.
In Formula 1-1, one bond of a bond between X2 and M, a bond between X3 and M, and a bond between X4 and M may be a covalent bond, while the remaining bonds may each be a coordinate bond. The organometallic compound represented by Formula 1-1 may be electrically neutral.
In some embodiments, a bond between X2 and M and a bond between X4 and M may each be a coordinate bond, and a bond between X3 and M may be a covalent bond.
X51 in Formula 1-1 may be O, S, N-[(L7)b7-(R7)c7], C(R7)(R8), Si(R7)(R8), Ge(R7)(R8), or C(═O). Each of R7, b7, R8 and b8 may be understood by referring to the description provided herein. R7 and R8 may optionally be bound to each other via a first linking group to form a C5-C30 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C30 heterocyclic group unsubstituted or substituted with at least one R10a.
In an embodiment, X51 in Formula 1-1 may be O, S, or N-[(L7)b7-(R7)c7].
In an embodiment, X51 in Formula 1-1 may be N-[(L7)b7-(R7)c7].
In Formula 1-1,
Z11 may be N or C-[(L11)b11-(T11)c11], Z12 may be N or C-[(L12)b12-(T12)c12], Z13 may be N or C-[(L13)b13-(T13)c13], and Z14 may be N or C-[(L14)b14-(T14)c14],
Z21 may be N or C-[(L21)b21-(T21)c21], Z22 may be N or C-[(L22)b22-(T22)c22], and Z23 may be N or C-[(L23)b23-(T23)c23],
Z31 may be N or C-[(L31)b31-(T31)c31], Z32 may be N or C-[(L32)b32-(T32)c32], and Z33 may be N or C-[(L33)b33-(T33)c33], and
Z41 may be N or C-[(L41)b41-(T41)c41], Z42 may be N or C-[(L42)b42-(T42)c42], Z43 may be N or C-[(L43)b43-(T43)c43], and Z44 may be N or C-[(L44)b44-(T44)c44].
In an embodiment, none of Z11 to Z14, none of Z21 to Z23, none of Z31 to Z33 and none of Z41 to Z44 may be N.
In Formula 1-1, L7, L11 to L14, L21 to L23, L31 to L33 and L41 to L44 may each independently be a single bond, a C1-C10 alkylene group unsubstituted or substituted with at least one R10a, a C5-C30 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C30 heterocyclic group unsubstituted or substituted with at least one R10a.
For example, in Formula 1-1, L7, L11 to L14, L21 to L23, L31 to L33 and L41 to L44 may each independently be:
a single bond; or
a methylene group, an ethylene group, a cyclopentane group, a cyclohexane group, a cycloheptane group, a cyclopentene group, a cyclohexene group, a cycloheptene group, an adamantane group, norbornane group, a norbornene group, a bicyclo[1.1.1]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.2]octane group, a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, or a benzothiadiazole group, each unsubstituted or substituted with at least one R10a.
In some embodiments, in Formula 1-1, L7, L11 to L14, L21 to L23, L31 to L33 and L41 to L44 may each independently be:
a single bond; or
a methylene group, a cyclopentane group, a cyclohexane group, a cycloheptane group, a cyclopentene group, a cyclohexene group, a cycloheptene group, an adamantane group, a norbornane group, a norbornene group, a bicyclo[1.1.1]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.2]octane group, a benzene group, or a naphthalene group, each unsubstituted or substituted with at least one R10a.
In Formula 1-1, b7, b11 to b14, b21 to b23, b31 to b33 and b41 to b44 may respectively indicate the number of L7, L11 to L14, L21 to L23, L31 to L33 and L41 to L44, and b7, b11 to b14, b21 to b23, b31 to b33 and b41 to b44 may each independently be 1, 2, 3, 4, or 5. For example, in Formula 1-1, b7, b11 to b14, b21 to b23, b31 to b33 and b41 to b44 may each independently be 1, 2, or 3.
In Formula 1-1, R″′, R7, R8, T11 to T14, T21 to T23, T31 to T33 and T41 to T44 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, —SF5, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q1)(Q2), —Si(Q3)(Q4)(Q5), —Ge(Q3)(Q4)(Q5), —B(Q6)(Q7), —P(═O)(Q8)(Q), or —P(Q8)(Q). Q1 to Q9 may respectively be understood by referring to the descriptions of Q1 to Q3 provided herein.
For example, in Formula 1-1, R″′, R7, R8, T11 to T14, T21 to T23, T31 to T33 and T41 to T44 may each independently be:
hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF5, a C1-C20 alkyl group, or a C1-C20 alkoxy group;
a C2-C10 alkyl group or a C2-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.2]octyl group, a (C1-C20 alkyl)cyclopentyl group, a (C1-C20 alkyl)cyclohexyl group, a (C1-C20 alkyl)cycloheptyl group, a (C1-C20 alkyl)cyclooctyl group, a (C1-C20 alkyl)adamantanyl group, a (C1-C20 alkyl)norbornanyl group, a (C1-C20 alkyl)norbornenyl group, a (C1-C20 alkyl)cyclopentenyl group, a (C1-C20 alkyl)cyclohexenyl group, a (C1-C20 alkyl)cycloheptenyl group, a (C1-C20 alkyl)bicyclo[1.1.1]pentyl group, a (C1-C20 alkyl)bicyclo[2.1.1]hexyl group, a (C1-C20 alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a (C1-C20 alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof; or
a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.2]octyl group, a phenyl group, a (C1-C20 alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, a benzoisoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group or an azadibenzothiophenyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.2]octyl group, a (C1-C20 alkyl)cyclopentyl group, a (C1-C20 alkyl)cyclohexyl group, a (C1-C20 alkyl)cycloheptyl group, a (C1-C20 alkyl)cyclooctyl group, a (C1-C20 alkyl)adamantanyl group, a (C1-C20 alkyl)norbornanyl group, a (C1-C20 alkyl)norbornenyl group, a (C1-C20 alkyl)cyclopentenyl group, a (C1-C20 alkyl)cyclohexenyl group, a (C1-C20 alkyl)cycloheptenyl group, a (C1-C20 alkyl)bicyclo[1.1.1]pentyl group, a (C1-C20 alkyl)bicyclo[2.1.1]hexyl group, a (C1-C20 alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a (C1-C20 alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, a benzoisoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, or any combination thereof; or
—N(Q1)(Q2), —Si(Q3)(Q4)(Q5), —Ge(Q3)(Q4)(Q5), —B(Q6)(Q7), —P(═O)(Q8)(Q9), or —P(Q8)(Q8),
wherein Q1 to Q9 may each independently be:
—CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2;
an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, a phenyl group, a biphenyl group, or a naphthyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, or any combination thereof.
In some embodiments, in Formula 1-1, R″′, R7, R8, T11 to T14, T21 to T23, T31 to T33 and T41 to T44 may each independently be:
hydrogen, deuterium, —F, or a cyano group; or
a C1-C20 alkyl group, a C3-C10 cycloalkyl group, a phenyl group, a biphenyl group or a naphtyl group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C20 alkyl group, a deuterated C1-C20 alkyl group, a fluorinated C1-C20 alkyl group, a C3-C10 cycloalkyl group, a (C1-C20 alkyl)C3-C10 cycloalkyl group, a deuterated C3-C10 cycloalkyl group, a fluorinated C3-C10 cycloalkyl group, or any combination thereof.
In Formula 1-1, c7, c11 to c14, c21 to c23, c31 to c33 and c41 to c44 may respectively indicate the number of R7, T11 to T14, T21 to T23, T31 to T33 and T41 to T44, and c7, c11 to c14, c21 to c23, c31 to c33 and c41 to c44 may each independently be 1, 2, 3, 4, or 5. For example, c7, c11 to c14, c21 to c23, c31 to c33 and c41 to c44 may each independently be 1 or 2.
The organometallic compound represented by Formula 1-1 may satisfy:
1) one of Condition 11, Condition 12 and Condition 13,
2) Condition 11 and Condition 13, or
3) Condition 12 and Condition 13.
Z42 in Formula 1-1 is C-[(L42)b42-(T42)c42], Condition 11
T42 is a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, or a substituted or unsubstituted C1-C10 heterocycloalkenyl group, and
c42 is 1.
Z42 in Formula 1-1 is C-[(L42)b42-(T42)c42], Condition 12
T42 is a group represented by Formula 41, and
c42 is 1:
*—C(Q41)(Q42)(Q43) Formula 41
wherein in Formula 41,
Q41 to Q43 are each independently deuterium, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,
at least one of Q41 to Q43 are each independently a substituted or unsubstituted C2-C60 alkyl group, a substituted or unsubstituted C3-C10 cycloalkyl group, or a substituted or unsubstituted C6-C60 aryl group, and
* indicates a binding site to an adjacent atom.
X51 in Formula 1-1 is N-[(L7)b7-(R7)c7], Condition 13
L7 is a benzene group, or a naphthalene group, each unsubstituted or substituted with at least one R10a,
R7 is a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, or a substituted or unsubstituted C1-C10 heterocycloalkenyl group, and
c7 is 1.
In some embodiments, the organometallic compound represented by Formula 1-1 may satisfy Condition 11 or Condition 12.
In some embodiments, the organometallic compound represented by Formula 1-1 may satisfy Condition 11 and L42 may be a benzene group, or a naphthalene group, each unsubstituted or substituted with at least one R10a.
In some embodiments, the organometallic compound represented by Formula 1-1 may satisfy Condition 12 and L42 may be a benzene group, or a naphthalene group, each unsubstituted or substituted with at least one R10a.
In some embodiments, the organometallic compound represented by Formula 1-1 may satisfy Condition 11 or Condition 13, and T42 and R7 may each independently be a C3-C10 cycloalkyl group unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C20 alkyl group, a deuterated C1-C20 alkyl group, a fluorinated C1-C20 alkyl group, a phenyl group, a (C1-C20 alkyl) phenyl group, a deuterated phenyl group, or a fluorinated phenyl group.
In some embodiments, the organometallic compound represented by Formula 1-1 may satisfy Condition 12, and Q41 to Q43 in Formula 41 may each independently be: deuterium; or
a C1-C20 alkyl group, a C3-C10 cycloalkyl group, a phenyl group, a biphenyl group or a naphtyl group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C20 alkyl group, a deuterated C1-C20 alkyl group, a fluorinated C1-C20 alkyl group, a C3-C10 cycloalkyl group, a (C1-C20 alkyl) C3-C10 cycloalkyl group, a deuterated C3-C10 cycloalkyl group, a fluorinated C3-C10 cycloalkyl group, or any combination thereof.
In some embodiments, the organometallic compound represented by Formula 1-1 may satisfy Condition 12 and at least one of Q41 to Q43 in Formula 41 may each independently be a C2-C20 alkyl group, a C3-C10 cycloalkyl group, a phenyl group, a biphenyl group or a naphtyl group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C20 alkyl group, a deuterated C1-C20 alkyl group, a fluorinated C1-C20 alkyl group, a C3-C10 cycloalkyl group, a (C1-C20 alkyl) C3-C10 cycloalkyl group, a deuterated C3-C10 cycloalkyl group, or a fluorinated C3-C10 cycloalkyl group.
Each of i) at least two of T11 to T14, ii) at least two of T21 to T23, iii) at least two of T31 to T33, iv) at least two of T41 to T44 and v) at least two of T11 to T14, T21 to T23, T31 to T33, and T41 to T44 may optionally be bound to each other to form a C5-C30 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C30 heterocyclic group unsubstituted or substituted with at least one R10a.
R10a may be understood by referring to the description of T11 provided herein, and
a substituent of the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C3-C10 cycloalkyl group, the substituted C1-C10 heterocycloalkyl group, the substituted C3-C10 cycloalkenyl group, the substituted C1-C10 heterocycloalkenyl group, the substituted C6-C60 aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C1-C60 heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be:
deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group;
a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), —Ge(Q13)(Q14)(Q15), —B(Q16)(Q17), —P(═O)(Q18)(Q19), —P(Q18)(Q19), or any combination thereof;
a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C0 aryl group, a C6-C0 aryloxy group, a C6-C60 arylthio group, a C1-C0 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), —Ge(Q23)(Q24)(Q25), —B(Q26)(Q27), —P(═O)(Q28)(Q29), —P(Q28)(Q29), or any combination thereof;
—N(Q31)(Q32), —Si(Q33)(Q34)(Q35), —Ge(Q33)(Q34)(Q35), —B(Q36)(Q37), —P(═O)(Q38)(Q39), or —P(Q38)(Q39); or
any combination thereof,
wherein Q1 to Q9, Q11 to Q19, Q21 to Q29, and Q31 to Q39 may each independently be: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; an amidino group; a hydrazine group; a hydrazone group; a carboxylic acid group or a salt thereof; a sulfonic acid group or a salt thereof; a phosphoric acid group or a salt thereof; a C1-C60 alkyl group unsubstituted or substituted with deuterium, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; a C3-C10 cycloalkyl group; a C1-C10 heterocycloalkyl group; a C3-C10 cycloalkenyl group; a C1-C10 heterocycloalkenyl group; a C6-C0 aryl group unsubstituted or substituted with deuterium, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof; a C6-C60 aryloxy group; a C6-C60 arylthio group; a C1-C60 heteroaryl group; a monovalent non-aromatic condensed polycyclic group; or a monovalent non-aromatic condensed heteropolycyclic group.
In an embodiment, in Formula 1-1, X51 may be N-[(L7)b7-(R7)c7], and the group represented by *-[(L7)b7-(R7)c7] may be a group represented by Formula N51:
wherein, in Formula N51, ring CY51 may be a C5-C30 carbocyclic group or a C1-C30 heterocyclic group. For example, ring CY51 may be a benzene group or a naphthalene group.
In Formula N51, L51, b51, R51, and c51 may respectively be understood by referring to the descriptions of L7, b7, R7, and c7 provided herein, and R52 and c52 may respectively be understood by referring to the descriptions of R7 and c7 provided herein.
In Formula N51, A51 may be a C1-C60 alkyl group unsubstituted or substituted with a C3-C10 cycloalkyl group. For example, A51 may be a C1-C20 alkyl group unsubstituted or substituted with a C3-C10 cycloalkyl group or a C4-C20 alkyl group unsubstituted or substituted with a C3-C10 cycloalkyl group.
In Formula N51, A52 may be a deuterated C1-C60 alkyl group unsubstituted or substituted with a C3-C10 cycloalkyl group. For example, A52 may be a deuterated C1-C20 alkyl group unsubstituted or substituted with a C3-C10 cycloalkyl group.
When X51 in Formula 1-1 is N-[(L7)b7-(R7)c7] and the group represented by *-[(L7)b7-(R7)c7] is a group represented by Formula N51, an angle between a plane including a transition dipole moment of the organometallic compound and a plane including four atoms of a tetradentate ligand bound to a metal (M) in Formula 1-1 may be 10° or less. In addition, a horizontal orientation ratio of a transition dipole moment of the organometallic compound represented by Formula 1-1 may be in a range of about 80% to about 100%.
For example, an angle between a plane including a transition dipole moment of the organometallic compound and a plane including four atoms of a tetradentate ligand bound to a metal (or platinum) in Formula 1-1 may be in a range of about 0° to about 10°, about 0° to about 9°, about 0° to about 8°, about 0° to about 7°, about 0° to about 6°, about 0° to about 5°, about 0° to about 4°, about 0° to about 3°, about 0° to about 2°, or about 0° to about 1°. As an angle between a plane including a transition dipole moment of the organometallic compound represented by Formula 1-1 and a plane including four atoms bound to a metal in Formula 1-1 is within any of these ranges, the organometallic compound may have excellent planar properties, and a thin film formed using the organometallic compound may have excellent electrical characteristics.
In an embodiment, A51 may be a linear or branched C4-C10 alkyl group, and A52 may be a hydrogen-free deuterated C1-C10 alkyl group.
In one or more embodiments, A51 may be an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, or a sec-isopentyl group.
In one or more embodiments, A52 may be a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, or a sec-isopentyl group, each substituted with at least one deuterium (or a hydrogen-free methyl group, a hydrogen-free ethyl group, a hydrogen-free n-propyl group, a hydrogen-free iso-propyl group, a hydrogen-free n-butyl group, a hydrogen-free sec-butyl group, a hydrogen-free isobutyl group, a hydrogen-free tert-butyl group, a hydrogen-free n-pentyl group, a hydrogen-free tert-pentyl group, a hydrogen-free neopentyl group, a hydrogen-free isopentyl group, a hydrogen-free sec-pentyl group, a hydrogen-free 3-pentyl group, or a hydrogen-free sec-isopentyl group, each substituted with at least one deuterium).
In one or more embodiments, in Formulae 1-1 and N51, R″′, R7, R8, T11 to T14, T21 to T23, T31 to T33, T41 to T44, R51, and R52 may each independently be hydrogen, deuterium, —F, a cyano group, a nitro group, —SF5, —CH3, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a group represented by one of Formulae 9-1 to 9-39, a group represented by one of Formulae 9-1 to 9-39 in which at least one hydrogen is substituted with deuterium, a group represented by one of Formulae 9-201 to 9-237, a group represented by one of 9-201 to 9-237 in which at least one hydrogen is substituted with deuterium, a group represented by one of Formulae 10-1 to 10-129, a group represented by one of Formulae 10-1 to 10-129 in which at least one hydrogen is substituted with deuterium, a group represented by one of Formulae 10-201 to 10-350, a group represented by one of Formulae 10-201 to 10-350 in which at least one hydrogen is substituted with deuterium, —Si(Q3)(Q4)(Q5), or —Ge(Q3)(Q4)(Q5), wherein Q3 to Q5 may respectively be understood by referring to the descriptions of Q3 to Q5 provided herein.
In one or more embodiments, in Formula N51, A51 may be a group represented by one of Formulae 9-4 to 9-39.
In one or more embodiments, in Formula N51, A52 may be a group represented by one of Formulae 9-1 to 9-39 in which at least one hydrogen is substituted with deuterium.
In one or more embodiments, in Formula N51, a group represented by
may be a group represented by one of Formulae 10-12 to 10-129:
In Formulae 9-1 to 9-39, 9-201 to 9-237, 10-1 to 10-129, and 10-201 to 10-350, * indicates a binding site to an adjacent atom, “Ph” represents a phenyl group, “TMS” represents a trimethylsilyl group, and “TMG” represents a trimethylgermyl group.
The “group represented by one of Formulae 9-1 to 9-39 in which at least one hydrogen is substituted with deuterium” and the “group represented by one of Formulae 9-201 to 9-237 in which at least one hydrogen is substituted with deuterium” may each be, for example, a group represented by one of Formulae 9-501 to 9-514 and 9-601 to 9-636:
The “group represented by one of Formulae 10-1 to 10-129 in which at least one hydrogen is substituted with deuterium” and the “group represented by one of Formulae 10-201 to 10-350 in which at least one hydrogen is substituted with deuterium” may each be, for example, a group represented by one of Formulae 10-501 to 553:
In some embodiments, in Formula N51, A52 may be a group represented by one of Formulae 9-1 to 9-39 in which all hydrogens are substituted with deuterium atoms.
In one or more embodiments, in Formula 1-1, X51 may be N-[(L7)b7-(R7)c7], and a group represented by *-[(L7)b7-(R7)c7] may be a phenyl group substituted with both 1) at least one C4-C10 alkyl group and 2) at least one phenyl group.
In one or more embodiments, in Formula 1-1, X51 may be N-[(L7)b7-(R7)c7], and a group represented by *-[(L7)b7-(R7)c7] may be a phenyl group substituted with both 1) at least one tert-butyl group and 2) at least one phenyl group.
In Formula N51, a51 and a52 may respectively indicate the number of A51(s) and A52(s), and a51 and a52 may each independently be an integer from 0 to 10. When a51 is 2 or greater, at least two A51(s) may be identical to or different from each other. When a52 is 2 or greater, at least two A2(s) may be identical to or different from each other.
For example, in Formula N51, a51 and a52 may each independently be 0, 1, 2, 3, 4, 5, or 6.
In Formula N51, a sum of a51 and a52 may be 1 or greater. That is, in Formula N51, ring CY51 is substituted with the group represented by A51, the group represented by A52, or any combination thereof. While not wishing to be bound by theory, ring CY51 is substituted with at least one electron donating group, and thus, an electronic device, e.g., an organic light-emitting device, including the organometallic compound represented by Formula 1-1 including the group represented by Formula N51 may have improved luminescence efficiency and lifespan.
In some embodiments, a sum of a51 and a52 may be 1, 2, or 3. In an embodiment, a sum of a51 and a52 may be 1.
In Formula N51, a53 indicates the number of a group represented by (R2)S2,
and a53 may be an integer from 1 to 10. That is, a53 in Formula N51 may not be 0, and thus ring CY51 in Formula N51 is substituted with at least one group represented by
While not wishing to be bound by theory, due to resonance effects of the group represented by
an electronic device, e.g., an organic light-emitting device, including the organometallic compound represented by Formula 1-1 including the group represented by Formula N51, may have improved luminescence efficiency and lifespan. While not wishing to be bound by theory, because a benzimidazole group in Formula 1-1 including the group represented by Formula N51 may be protected from electrons or heat by the group represented by
an electronic device, e.g., an organic light-emitting device, including the organometallic compound represented by Formula 1-1 may have improved luminescence efficiency and lifespan.
In an embodiment, in Formula N51, a51 and a52 may each independently be 0, 1, or 2 (e.g., 0 or 1), and a sum of a51 and a52 may be 1 or 2 (e.g., 1), and a53 may be 1 or 2 (e.g., 1).
In Formula N51, * indicates a binding site to an adjacent atom.
In one or more embodiments, in Formula N51, the group represented by
may be a group represented by one of Formulae 51-1 to 51-20:
wherein, in Formulae 51-1 to 51-20, R51, R52, c51, c52, A51, and A52 may respectively be understood by referring to the descriptions of R51, R52, c51, c52, A51, and A52 provided herein, and * indicates a binding site to L51.
In one or more embodiments, in Formula 1-1, each of Z12 and Z14 may be C(H).
In one or more embodiments, in Formula 1-1, each of Z11 may be C-[(L11)b11-(T11)c11] and T11 may not be hydrogen.
In one or more embodiments, in Formula 1-1, each of Z13 may be C-[(L13)b13-(T13)c13] and T13 may not be hydrogen.
In one or more embodiments, in Formula 1-1, each of Z21 to Z22 may be C(H).
In one or more embodiments, in Formula 1-1, each of Z31 and Z33 may be C(H).
In one or more embodiments, in Formula 1-1,
Z32 may be C-[(L32)b32-(T32)c32],
L32 may be a single bond, and
T32 may be a substituted or unsubstituted C1-C0 alkyl group or a substituted or unsubstituted C6-C0 aryl group.
In one or more embodiments, in Formula 1-1, each of Z41, Z43 and Z44 may be C(H).
In one or more embodiments, in Formula 1-1, each of Z42 may be C-[(L42)b42-(T42)c42] and T42 may not be hydrogen.
In one or more embodiments, in Formula 1-1,
Z11 may be C-[(L11)b11-(T11)c11], Z12 may be C-[(L12)b12-(T12)c12], Z13 may be C-[(L13)b13-(T13)c13], Z14 may be C-[(L14)b14-(T14)c14], Z31 may be C-[(L31)b31-(T31)c31], Z32 may be C-[(L32)b32-(T32)c32], Z33 may be C-[(L33)b33-(T33)c33],
at least one of T11 to T14, at least one of T31 to T33, or any combination thereof may each independently be:
a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, or a sec-isopentyl group, each unsubstituted or substituted with at least one deuterium, —F, a cyano group, or any combination thereof; or
a phenyl group, or naphtyl group, each unsubstituted or substituted with at least one deuterium, —F, a cyano group, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, or a sec-isopentyl group, or any combination thereof.
In one or more embodiments, in Formula 1-1, a group represented by
may be represented by one of Formulae A1-1 to A1-9:
wherein, in Formulae A1-1 to A1-9,
Y1, Z11 to Z14 and R10a may respectively be understood by referring to the descriptions of Y1, Z11 to Z14 and R10a provided herein,
ring CY11 may be a C5-C30 carbocyclic group or a C1-C30 heterocyclic group (for example, a cyclohexane group, a norbornane group, a benzene group, or a naphthalene group),
X11 may be O, S, N(R11), C(R11)(R12), or Si(R11)(R12),
R11 and R12 may each be understood by referring to the description of T11 provided herein,
aa may be an integer from 0 to 6,
*′ indicates a binding site to X1 in Formula 1-1, and
* indicates a binding site to an adjacent atom.
In one or more embodiments, in Formula 1-1, a group represented by
may be represented by one of Formulae A3-1 to A3-6:
wherein, in Formulae A3-1 to A3-1,
X3, Z31 to Z33 and R10a may respectively be understood by referring to the descriptions of X3, Z31 to Z33 and R10a provided herein,
ring CY31 may be a C5-C30 carbocyclic group or a C1-C30 heterocyclic group (for example, a cyclohexane group, a norbornane group, a benzene group, or a naphthalene group),
X31 may be O, S, N(R31), C(R31)(R32), or Si(R31)(R32),
R31 and R32 may each be understood by referring to the description of T31 provided herein,
aa may be an integer from 0 to 6,
each of *″ and * indicates a binding site to an adjacent atom,
*′ indicates a binding site to M in Formula 1-1.
In one or more embodiments, in Formula 1-1, a group represented by
may be represented by one of Formulae A4-1 to A4-9:
wherein, in Formulae A4-1 to A4-9,
X4, Z41 to Z44 and R10a may respectively be understood by referring to the descriptions of X4, Z41 to Z44 and R10a provided herein,
ring CY41 may be a C5-C30 carbocyclic group or a C1-C30 heterocyclic group (for example, a cyclohexane group, a norbornane group, a benzene group, or a naphthalene group),
X41 may be O, S, N(R41), C(R41)(R42), or Si(R41)(R42),
R41 and R42 may each be understood by referring to the description of T41 provided herein,
aa may be an integer from 0 to 6,
*′ indicates a binding site to M in Formula 1-1, and
* indicates a binding site to an adjacent atom in Formula 1-1.
In one or more embodiments, the organometallic compound represented by Formula 1-1 may include at least one deuterium.
The organometallic compound represented by Formula 1-1 may be one of the Compounds 1 to 420:
The organometallic compound represented by Formula 1-1 may have excellent electrical characteristics and thermal stability. Thus, an organic light-emitting device having a high luminescence efficiency may be manufactured.
A method of synthesizing the organometallic compound may be apparent to one of ordinary skill in the art by referring to Synthesis Examples provided herein.
Accordingly, the organometallic compound may be suitable for use in an organic layer of an organic light-emitting device, e.g., as a dopant in the organic layer. Thus, according to another aspect, there is provided an organic light-emitting device that may include a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, wherein the organic layer may include at least one organometallic compound represented by Formula 1-1.
The organic light-emitting device may include an organic layer including the organometallic compound. Thus, the organic light-emitting device may have excellent driving voltage, excellent luminescence efficiency and external quantum efficiency characteristics.
The organometallic compound may be used in a pair of electrodes of an organic light-emitting device. In some embodiments, the organometallic compound may be included in an emission layer. In this embodiment, the organometallic compound may serve as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound may be smaller than that of the host in the emission layer). The emission layer may emit red light or green light, e.g., red light or green light having a maximum emission wavelength of about 500 nanometers (nm) or longer, e.g., about 500 nm to about 650 nm.
In some embodiments, the emission layer may emit green light.
As used herein, the expression the “(organic layer) includes at least one organometallic compound” may be construed as meaning the “(organic layer) may include one organometallic compound of Formula 1-1 or two different organometallic compounds of Formula 1-1”.
For example, Compound 1 may only be included in the organic layer as an organometallic compound. In this embodiment, Compound 1 may be included in the emission layer of the organic light-emitting device. In some embodiments, Compounds 1 and 2 may be included in the organic layer as organometallic compounds. In this embodiment, Compounds 1 and 2 may both be included in the same layer (for example, both Compounds 1 and 2 may be included in the emission layer).
The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode. In some embodiments, the first electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.
For example, in the organic light-emitting device, the first electrode may be an anode, the second electrode may be a cathode, and the organic layer may further include a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode, wherein the hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or a combination thereof, and the electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or a combination thereof.
The term “organic layer” as used herein refers to a single and/or a plurality of layers between the first electrode and the second electrode in an organic light-emitting device. The “organic layer” may include not only organic compounds but also organometallic complexes including metals.
The FIGURE illustrates a schematic cross-sectional view of an organic light-emitting device 10 according to an exemplary embodiment. Hereinafter, a structure of an organic light-emitting device according to one or more embodiments and a method of manufacturing the organic light-emitting device will be described with reference to the FIGURE. The organic light-emitting device 10 may include a first electrode 11, an organic layer 15, and a second electrode 19, which may be sequentially layered in this stated order.
A substrate may be additionally disposed under the first electrode 11 or on the second electrode 19. The substrate may be a conventional substrate used in organic light-emitting devices, e.g., a glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water repellency.
The first electrode 11 may be formed by depositing or sputtering, onto the substrate, a material for forming the first electrode 11. The first electrode 11 may be an anode. The material for forming the first electrode 11 may include a material with a high work function for easy hole injection. The first electrode 11 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode 11 may be indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO2), or zinc oxide (ZnO). In some embodiments, the material for forming the first electrode 11 may be a metal, such as magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag).
The first electrode 11 may have a single-layered structure or a multi-layered structure including a plurality of layers. In some embodiments, the first electrode 11 may have a triple-layered structure of ITO/Ag/ITO.
The organic layer 15 may be on the first electrode 11.
Organic layer 15 in organic light-emitting device 10
The organic layer 15 may include a hole transport region, an emission layer, and an electron transport region.
The hole transport region may be between the first electrode 11 and the emission layer.
The hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or a combination thereof.
The hole transport region may include a hole injection layer only or a hole transport layer only. In some embodiments, the hole transport region may include a hole injection layer and a hole transport layer which are sequentially stacked on the first electrode 11. In some embodiments, the hole transport region may include a hole injection layer, a hole transport layer, and an electron blocking layer, which are sequentially stacked on the first electrode 11.
When the hole transport region includes a hole injection layer, the hole injection layer may be formed on the first electrode 11 by using one or more suitable methods, such as vacuum deposition, spin coating, casting, and Langmuir-Blodgett (LB) deposition.
When a hole injection layer is formed by vacuum-deposition, for example, the vacuum deposition may be performed at a temperature in a range of about 100° C. to about 500° C., at a vacuum pressure in a range of about 10−8 torr to about 10−3 torr, and at a rate in a range of about 0.01 Angstroms per second (Å/sec) to about 100 Å/sec, though the conditions may vary depending on a compound used as a hole injection material and a structure and thermal properties of a desired hole injection layer.
When a hole injection layer is formed by spin coating, the spin coating may be performed at a rate in a range of about 2,000 revolutions per minute (rpm) to about 5,000 rpm and at a temperature in a range of about 80° C. to 200° C. to facilitate removal of a solvent after the spin coating, though the conditions may vary depending on a compound used as a hole injection material and a structure and thermal properties of a desired hole injection layer.
The conditions for forming a hole transport layer and an electron blocking layer may be inferred from the conditions for forming the hole injection layer.
The hole transport region may include m-MTDATA, TDATA, 2-TNATA, NPB, 3-NPB, TPD, spiro-TPD, spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4′,4″-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzenesulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate) (PEDOT/PSS), polyaniline/camphor-sulfonic acid (PANI/CSA), polyaniline/poly(4-styrene sulfonate) (PANI/PSS), a compound represented by Formula 201, a compound represented by Formula 202, or any combination thereof:
wherein, in Formula 201, Ar101 and Ar102 may each independently be a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, or a pentacenylene group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, or any combination thereof.
In Formula 201, xa and xb may each independently be an integer from 0 to 5. In some embodiments, xa and xb may each independently be an integer from 0 to 2. In some embodiments, xa may be 1, and xb may be 0.
In Formulae 201 and 202, R101 to R108, R111 to R119, and R121 to R124 may each independently be:
hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C10 alkyl group (e.g., a methyl group, an ethyl group, a propyl group, a butyl group, pentyl group, or a hexyl group), or a C1-C10 alkoxy group (e.g., a methoxy group, an ethoxy group, a propoxy group, a butoxy group, or a pentoxy group);
a C1-C10 alkyl group or a C1-C10 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, or any combination thereof; or
a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, or a pyrenyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C10 alkyl group, a C1-C10 alkoxy group, or any combination thereof.
In Formula 201, R109 may be a phenyl group, a naphthyl group, an anthracenyl group, or a pyridinyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyridinyl group, or any combination thereof.
In some embodiments, the compound represented by Formula 201 may be represented by Formula 201A:
wherein, in Formula 201A, R101, R111, R112, and R109 may respectively be understood by referring to the descriptions of R101, R111, R112, and R109 provided herein.
In some embodiments, the hole transport region may include one of Compounds HT1 to HT21 or any combination thereof:
The thickness of the hole transport region may be in a range of about 100 Angstroms (Å) to about 10,000 Å, for example, about 100 Å to about 3,000 Å. When the hole transport region includes a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, the thickness of the hole injection layer may be in a range of about 50 Å to about 10,000 Å, for example, about 100 Å to about 1,000 Å, the thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, for example, about 100 Å to about 1,500 Å. When the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within any of these ranges, excellent hole transport characteristics may be obtained without a substantial increase in driving voltage.
The hole transport region may include a charge generating material as well as the aforementioned materials, to improve conductive properties of the hole transport region. The charge generating material may be substantially homogeneously or non-homogeneously dispersed in the hole transport region.
The charge generating material may include, for example, a p-dopant. The p-dopant may be a quinone derivative, a metal oxide, a compound containing a cyano group, or any combination thereof. In some embodiments, the p-dopant may be a quinone derivative, such as tetracyanoquinodimethane (TCNQ), a 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonedimethane (F4-TCNQ), or F6-TCNNQ; a metal oxide, such as a tungsten oxide or a molybdenum oxide; a compound containing a cyano group, such as Compound HT-D1; or any combination thereof:
The hole transport region may further include a buffer layer.
The buffer layer may compensate for an optical resonance distance depending on a wavelength of light emitted from the emission layer to improve the efficiency of an organic light-emitting device.
When the hole transport region includes an electron blocking layer, a material for forming the electron blocking layer may include the material for forming a hole transport region, the host material described herein or any combination thereof. In some embodiments, when the hole transport region includes an electron blocking layer, mCP described herein, Compound H21, H-H1, or any combination thereof may be used for forming the electron blocking layer.
An emission layer may be formed on the hole transport region by using one or more suitable methods, such as vacuum deposition, spin coating, casting, or LB deposition. When the emission layer is formed by vacuum deposition or spin coating, vacuum deposition and coating conditions for forming the emission layer may be generally similar to those conditions for forming a hole injection layer, though the conditions may vary depending on a compound that is used.
The emission layer may include a host and a dopant, and the dopant may include the organometallic compound represented by Formula 1-1 described herein.
The host may include TPBi, TBADN, ADN (also known as “DNA”), CBP, CDBP, TCP, mCP, Compound H50, Compound H51, Compound H52, or any combination thereof:
The host may consist of one type of compound or a mixture of at least two different kinds of compounds.
In an embodiment, the host may include an electron transporting host including at least one electron transporting moiety, a hole transporting host not including an electron transporting moiety, or any combination thereof.
The electron transporting moiety may include a cyano group, a π electron-depleted nitrogen-containing cyclic group, a group represented by one of following Formulae, or any combination thereof:
wherein, in the Formulae above, *, *′, and *″ may each indicate a binding site to an adjacent atom.
For example, the electron transporting host may include at least one π electron-rich cyclic group and at least one electron transporting moiety.
In some embodiments, the hole transporting host may include at least one π electron-rich cyclic group and not include an electron transporting moiety.
In one or more embodiments, the host may include an electron transporting host and a hole transporting host, and the electron transporting host may be different from the hole transporting host.
The term “π electron-depleted nitrogen-containing cyclic group” as used herein refers to a cyclic group having at least one *—N=*′ moiety. Examples thereof may include an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyridazine group, a pyrimidine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an isobenzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, and an azacarbazole group.
The π electron-rich cyclic group refers to a cyclic group not including a *—N=*′ moiety. Examples thereof may include a benzene group, a heptalene group, an indene group, a naphthalene group, an azulene group, an indacene group, acenaphthylene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentacene group, a hexacene group, a rubicene group, a coronene group, an ovalene group, a pyrrole group, an isoindole group, an indole group, a furan group, a thiophene group, a benzofuran group, a benzothiophene group, a benzocarbazole group, a dibenzocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzothiophene sulfone group, a carbazole group, a dibenzosilole group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, and a triindolobenzene group.
According to another embodiment, the electron transporting host may include a compound represented by Formula E-1.
In one or more embodiments, the hole transporting host may include a compound represented by Formula H-1.
[Ar301]xb11-[(L301)xb1-R301]xb21 Formula E-1
wherein, in Formula E-1,
Ar301 may be a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
xb11 may be 1, 2, or 3,
L301 may each independently be a single bond, a group represented by one of the Formulae below, a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, wherein in Formulae, *, *′, and *″ each indicate a binding site to an adjacent atom,
xb1 may be an integer from 1 to 5,
R301 may be hydrogen, deuterium, —F, —Cl, —Br, —I, —SF5, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C3-C10 cycloalkyl group, a substituted or unsubstituted C1-C10 heterocycloalkyl group, a substituted or unsubstituted C3-C10 cycloalkenyl group, a substituted or unsubstituted C1-C10 heterocycloalkenyl group, a substituted or unsubstituted C6-C60 aryl group, a substituted or unsubstituted C6-C60 aryloxy group, a substituted or unsubstituted C6-C60 arylthio group, a substituted or unsubstituted C1-C60 heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —Si(Q301)(Q302)(Q303), —N(Q301)(Q302), —B(Q301)(Q302), —C(═O)(Q301), —S(═O)2(Q301), —S(═O)(Q301), —P(═O)(Q301)(Q302), or —P(═S)(Q301)(Q302),
xb21 may be an integer from 1 to 5,
wherein Q301 to Q303 may each independently be a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group,
R10a may be understood by referring to the description of T11 provided herein, and at least one of Conditions 1 to 3 may be satisfied:
Condition 1
at least one of Ar301, L301, and R301 in Formula E-1 may each independently include a π electron-depleted nitrogen-containing cyclic group,
Condition 2
L301 in Formula E-1 may be a group represented by one of the following Formulae:
Condition 3
R301 in Formula E-1 may be a cyano group, —S(═O)2(Q301), —S(═O)(Q301), —P(═O)(Q301)(Q302), or —P(═S)(Q301)(Q302).
wherein, in Formulae H-1, 11, and 12,
L401 may be:
a single bond; or
a π electron-rich cyclic group (e.g., a benzene group, a heptalene group, an indene group, a naphthalene group, an azulene group, an indacene group, acenaphthylene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentacene group, a hexacene group, a rubicene group, a coronene group, an ovalene group, a pyrrole group, an isoindole group, an indole group, a furan group, a thiophene group, a benzofuran group, a benzothiophene group, a benzocarbazole group, a dibenzocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzothiophene sulfone group, a carbazole group, a dibenzosilole group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, or a triindolobenzene group) unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a C1-C10 alkoxy group, a π electron-rich cyclic group (e.g., a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a triphenylenyl group, a biphenyl group, a terphenyl group, or a tetraphenyl group (or, quaterphenyl)), —Si(Q401)(Q402)(Q403), or any combination thereof,
xd1 may be an integer from 1 to 10, and when xd1 is 2 or greater, at least two L401(s) may be identical to or different from each other,
Ar401 may be a group represented by Formula 11 or a group represented by Formula 12,
Ar402 may be:
a group represented by Formula 11 or a group represented by Formula 12; or
a π electron-rich cyclic group (e.g., a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group) unsubstituted or substituted with deuterium, a C1-C20 alkyl group, a C1-C20 alkoxy group, a π electron-rich cyclic group (e.g., a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group), or any combination thereof,
xd11 may be an integer from 0 to 10 (for example, an integer from 1 to 10), and when xd11 is 2 or greater, at least two Ar402(s) may be identical to or different from each other,
CY401 and CY402 may each independently be a π electron-rich cyclic group (e.g., a benzene group, a naphthalene group, a fluorene group, a carbazole group, a benzocarbazole group, an indolocarbazole group, a dibenzofuran group, a dibenzothiophene group, a dibenzosilole group, a benzonaphthofuran group, a benzonapthothiophene group, or a benzonaphthosilole group),
A21 may be a single bond, O, S, N(R51), C(R51)(R52), or Si(R51)(R52),
A22 may be a single bond, O, S, N(R53), C(R53)(R54), or Si(R53)(R54),
at least one of A21 and A22 in Formula 12 may not be a single bond,
R51 to R54 and R401 to R402 may each independently be:
hydrogen or deuterium;
a C1-C20 alkyl group and a C1-C20 alkoxy group, each unsubstituted or substituted with deuterium, a π electron-rich cyclic group (e.g., a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, or a dibenzothiophenyl group), or any combination thereof;
a π electron-rich cyclic group (e.g., a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group) unsubstituted or substituted with deuterium, a C1-C20 alkyl group, a C1-C20 alkoxy group, a π electron-rich cyclic group (e.g., a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a biphenyl group, a terphenyl group, or a triphenylenyl group), or any combination thereof,
—Si(Q404)(Q405)(Q406),
e1 and e2 may each independently be an integer from 0 to 10,
wherein Q401 to Q406 may each independently be hydrogen, deuterium, a C1-C20 alkyl group, a C1-C20 alkoxy group, or a π electron-rich cyclic group (e.g., a phenyl group, a naphthyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, or a biphenyl group), and
* indicates a binding site to an adjacent atom.
In an embodiment, in Formula E-1, Ar301 may be a naphthalene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, a dibenzofluorene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a naphthacene group, a picene group, a perylene group, a pentaphene group, an indenoanthracene group, a dibenzofuran group, or a dibenzothiophene group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof,
at least one of L301(s) in the number of xb1 may each independently be an imidazole group, a pyrazole group, a thiazole group, an isothiazole group, an oxazole group, an isoxazole group, a pyridine group, a pyrazine group, a pyridazine group, a pyrimidine group, an indazole group, a purine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a phthalazine group, a naphthyridine group, a quinoxaline group, a quinazoline group, a cinnoline group, a phenanthridine group, an acridine group, a phenanthroline group, a phenazine group, a benzimidazole group, an isobenzothiazole group, a benzoxazole group, an isobenzoxazole group, a triazole group, a tetrazole group, an oxadiazole group, a triazine group, a thiadiazole group, an imidazopyridine group, an imidazopyrimidine group, or an azacarbazole group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof, and
R301 may be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazino group, a hydrazono group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a tetraphenyl group, a naphthyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32),
wherein Q31 to Q33 may each independently be a C1-C10 alkyl group, a C1-C10 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, or a naphthyl group.
In one or more embodiments, R301 may be represented by one of Formulae 7-1 to 7-9:
The electron transporting host may be, for example, at least one of Compounds H-E1 to H-E84:
In some embodiments, the hole transporting host may be at least one of Compounds H-H1 to H-H103:
In some embodiments, the host may include an electron transporting host and a hole transporting host, the electron transporting host may include a triphenylene group and a triazine group, and the hole transporting host may include a carbazole group.
A weight ratio of the electron transporting host to the hole transporting host may be in a range of about 1:9 to about 9:1, for example, about 2:8 to about 8:2, or for example, about 4:6 to about 6:4. When a weight ratio of the electron transporting host to the hole transporting host is within any of these ranges, holes and electrons transport balance into the emission layer may be achieved.
When the organic light-emitting device 10 is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and/or a blue emission layer. In some embodiments, the emission layer may have a structure in which the red emission layer, the green emission layer, and/or the blue emission layer are layered to emit white light. In some embodiments, the structure of the emission layer may vary.
When the emission layer includes the host and the dopant, an amount of the dopant may be selected from a range of about 0.01 parts to about 15 parts by weight based on about 100 parts by weight of the host.
The thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, and in some embodiments, about 200 Å to about 600 Å. When the thickness of the emission layer is within any of these ranges, improved luminescence characteristics may be obtained without a substantial increase in driving voltage.
Next, an electron transport region may be formed on the emission layer.
The electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or a combination thereof.
In some embodiments, the electron transport region may have a hole blocking layer/an electron transport layer/an electron injection layer structure or an electron transport layer/an electron injection layer structure. The electron transport layer may have a single-layered structure or a multi-layered structure including two or more different materials.
The conditions for forming a hole blocking layer, an electron transport layer, and an electron injection layer may be inferred based on the conditions for forming the hole injection layer.
When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one of BCP, Bphen, BAlq, or any combination thereof:
In some embodiments, the hole blocking layer may include the host, the material for forming an electron transport layer described herein, the material for forming an electron injection layer described herein, or any combination thereof.
The thickness of the hole blocking layer may be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 600 Å. When the thickness of the hole blocking layer is within any of these ranges, excellent hole blocking characteristics may be obtained without a substantial increase in driving voltage.
The electron transport layer may include BCP, Bphen, TPBi, Alq3, BAlq, TAZ, NTAZ, or any combination thereof:
In some embodiments, the electron transport layer may include one of Compounds ET1 to ET25 or any combination thereof:
The thickness of the electron transport layer may be in a range of about 100 Å to about 1,000 Å, and in some embodiments, about 150 Å to about 500 Å. When the thickness of the electron transport layer is within any of these ranges, excellent electron transport characteristics may be obtained without a substantial increase in driving voltage.
The electron transport layer may further include a material containing metal, in addition to the materials described above.
The material containing metal may include a Li complex. The Li complex may include, e.g., Compound ET-D1 or Compound ET-D2:
The electron transport region may include an electron injection layer that facilitates electron injection from the second electrode 19.
The electron injection layer may include LiF, NaCl, CsF, Li2O, BaO, or any combination thereof.
The thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, and in some embodiments, about 3 Å to about 90 Å. When the thickness of the electron injection layer is within any of these ranges, excellent electron injection characteristics may be obtained without a substantial increase in driving voltage.
The second electrode 19 may be on the organic layer 15. The second electrode 19 may be a cathode. A material for forming the second electrode 19 may be a material with a relatively low work function, such as a metal, an alloy, an electrically conductive compound, or any combination thereof. Examples of the material for forming the second electrode 19 may include lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), and magnesium-silver (Mg—Ag). In some embodiments, ITO or IZO may be used to form a transmissive second electrode 19 to manufacture a top emission light-emitting device. In some embodiments, the material for forming the second electrode 19 may vary.
Hereinbefore the organic light-emitting device 10 has been described with reference to the FIGURE, but embodiments are not limited thereto.
According to an aspect of another embodiment, an electronic apparatus may include the organic light-emitting device. Thus, an electronic apparatus including the organic light-emitting device may be provided. The electronic apparatus may include, for example, a display, lighting, a sensor, or the like.
According to an aspect of still another embodiment, a diagnostic composition may include at least one organometallic compound represented by Formula 1-1.
Since the organometallic compound represented by Formula 1-1 provides high luminescence efficiency, the diagnostic efficiency of the diagnostic composition that includes the organometallic compound represented by Formula 1-1 may be excellent.
The diagnostic composition may be applied in various ways, such as in a diagnostic kit, a diagnostic reagent, a biosensor, or a biomarker.
The term “C1-C60 alkyl group” as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and the term “C1-C60 alkylene group” as used herein refers to a divalent group having the same structure as the C1-C60 alkyl group.
Examples of the C1-C60 alkyl group, the C1-C20 alkyl group, and/or the C1-C10 alkyl group as used herein may include a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group or a tert-decyl group, each unsubstituted or substituted with a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, an n-hexyl group, an iso-hexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an iso-heptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an iso-octyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an iso-nonyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an iso-decyl group, a sec-decyl group, a tert-decyl group, or any combination thereof. In some embodiments, Formula 9-33 may be a branched C6 alkyl group. Formula 9-33 may be a tert-butyl group substituted with two methyl groups.
The term “C1-C60 alkoxy group” as used herein refers to a monovalent group represented by —OA101 (wherein A101 is a C1-C60 alkyl group).
Examples of the C1-C60 alkoxy group, the C1-C20 alkoxy group, or the C1-C10 alkoxy group as used herein may include a methoxy group, an ethoxy group, a propoxy group, a butoxy group, or a pentoxy group.
The term “C2-C60 alkenyl group” as used herein refers to a group formed by placing at least one carbon-carbon double bond in the middle or at the terminus of the C2-C60 alkyl group. Examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C2-C60 alkenylene group” as used herein refers to a divalent group having the same structure as the C2-C60 alkenyl group.
The term “C2-C60 alkynyl group” as used herein refers to a group formed by placing at least one carbon-carbon triple bond in the middle or at the terminus of the C2-C60 alkyl group. Examples thereof include an ethynyl group and a propynyl group. The term “C2-C60 alkynylene group” as used herein refers to a divalent group having the same structure as the C2-C60 alkynyl group.
The term “C3-C10 cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon cyclic group having 3 to 10 carbon atoms. The term “C3-C10 cycloalkylene group” as used herein refers to a divalent group having the same structure as the C3-C10 cycloalkyl group.
Examples of the C3-C10 cycloalkyl group as used herein may include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group (a bicyclo[2.2.1]heptyl group), a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, or a bicyclo[2.2.2]octyl group.
The term “C1-C10 heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having 1 to 10 carbon atoms and at least one heteroatom of N, O, P, Si, S, Ge, Se and B as a ring-forming atom. The term “C1-C10 heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C1-C10 heterocycloalkyl group.
Examples of the C1-C10 heterocycloalkyl group as used herein may include a silolanyl group, a silinanyl group, a tetrahydrofuranyl group, a tetrahydro-2H-pyranyl group, or a tetrahydrothiophenyl group.
The term “C3-C10 cycloalkenyl group” as used herein refers to a monovalent cyclic group that has 3 to 10 carbon atoms and at least one carbon-carbon double bond in its ring, wherein the molecular structure as a whole is non-aromatic. Examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C3-C10 cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C3-C10 cycloalkenyl group.
The term “C1-C10 heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group including at least one heteroatom of N, O, P, Si, S, Ge, Se and B as a ring-forming atom, 1 to 10 carbon atoms, and at least one double bond in its ring. Examples of the C1-C10 heterocycloalkenyl group include a 2,3-dihydrofuranyl group and a 2,3-dihydrothiophenyl group. The term “C1-C10 heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C1-C10 heterocycloalkenyl group.
The term “C6-C60 aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. The term “C6-C60 arylene group” as used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Examples of the C6-C60 aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C6-C60 aryl group and the C6-C60 arylene group each include a plurality of rings, the plurality of rings may be fused to each other.
The term “C7-C60 alkyl aryl group” as used herein refers to a C6-C60 aryl group substituted with at least one C1-C60 alkyl group.
The term “C1-C60 heteroaryl group” as used herein refers to a monovalent group having a heterocyclic aromatic system having at least one heteroatom of N, O, P, Si, S, Ge, Se and B as a ring-forming atom and 1 to 1 carbon atoms. The term “C1-C60 heteroarylene group” as used herein refers to a divalent group having a heterocyclic aromatic system having at least one heteroatom of N, O, P, Si, S, Ge, Se and B as a ring-forming atom and 1 to 60 carbon atoms. Examples of the C1-C60 heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C1-C60 heteroaryl group and the C1-C60 heteroarylene group each include a plurality of rings, the plurality of rings may be fused to each other.
The term “C2-C60 alkyl heteroaryl group” as used herein refers to a C1-C60 heteroaryl group substituted with at least one C1-C60 alkyl group.
The term “C6-C60 aryloxy group” as used herein is represented by —OA102 (wherein A102 is the C6-C60 aryl group). The term “C6-C60 arylthio group” as used herein is represented by —SA1O3 (wherein A103 is the C6-C60 aryl group). The term “C1-C60 alkylthio group” as used herein is represented by —SA1O4 (wherein A104 is the C1-C6 alkyl group).
The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group that has two or more condensed rings and only carbon atoms (e.g., the number of carbon atoms may be in a range of 8 to 60) as ring-forming atoms, wherein the molecular structure as a whole is non-aromatic. Examples of the monovalent non-aromatic condensed polycyclic group include a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group” as used herein refers to a divalent group having substantially the same structure as the monovalent non-aromatic condensed polycyclic group.
The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group that has two or more condensed rings and a heteroatom selected from N, O, P, Si, S, Ge, Se and B and carbon atoms (e.g., the number of carbon atoms may be in a range of 1 to 60) as ring-forming atoms, wherein the molecular structure as a whole is non-aromatic. Examples of the monovalent non-aromatic condensed heteropolycyclic group include a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having substantially the same structure as the monovalent non-aromatic condensed heteropolycyclic group.
The term “C5-C30 carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group including 5 to 30 carbon atoms only as ring-forming atoms. The C5-C30 carbocyclic group may be a monocyclic group or a polycyclic group. Examples of the “C5-C30 carbocyclic group (unsubstituted or substituted with at least one R10a)” may include an adamantane group, a norbornene group, a bicyclo[1.1.1]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.1]heptane group (a norbornane group), a bicyclo[2.2.2]octane group, a cyclopentane group, a cyclohexane group, a cyclohexene group, a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a 1,2,3,4-tetrahydronaphthalene group, a cyclopentadiene group, or a fluorene group, each unsubstituted or substituted with at least one R10a.
The term “C1-C30 heterocyclic group” as used herein refers to saturated or unsaturated cyclic group including 1 to 30 carbon atoms and at least one heteroatom selected from N, O, P, Si, Se, Ge, B, and S as ring-forming atoms. The C1-C30 heterocyclic group may be a monocyclic group or a polycyclic group. Examples of the “C1-C30 heterocyclic group (unsubstituted or substituted with at least one R10a)” may include a thiophene group, a furan group, a pyrrole group, a silole group, a borole group, a phosphole group, a selenophene group, a germole group, a benzothiophene group, a benzofuran group, an indole group, a benzosilole group, a benzoborole group, a benzophosphole group, a benzoselenophene group, a benzogermole group, a dibenzothiophene group, a dibenzofuran group, a carbazole group, a dibenzosilole group, a dibenzoborole group, a dibenzophosphole group, a dibenzoselenophene group, a dibenzogermole group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azabenzothiophene group, an azabenzofuran group, an azaindole group, an azaindene group, an azabenzosilole group, an azabenzoborole group, an azabenzophosphole group, an azabenzoselenophene group, an azabenzogermole group, an azadibenzothiophene group, an azadibenzofuran group, an azacarbazole group, an azafluorene group, an azadibenzosilole group, an azadibenzoborole group, an azadibenzophosphole group, an azadibenzoselenophene group, an azadibenzogermole group, an azadibenzothiophene 5-oxide group, an aza-9H-fluoren-9-one group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, or a 5,6,7,8-tetrahydroquinoline group, each unsubstituted or substituted with at least one R10a.
Examples of the “C5-C30 carbocyclic group” and the “C1-C30 heterocyclic group” as used herein include i) a first ring, ii) a second ring, iii) a condensed ring in which at least two first rings are condensed, iv) a condensed ring in which at least two second rings are condensed, or v) a condensed ring in which at least one first ring and at least one second ring are condensed,
the first ring may be a cyclopentane group, a cyclopentene group, a furan group, a thiophene group, a pyrrole group, a silole group, a borole group, a phosphole group, a germole group, a selenophene group, an oxazole group, an isoxazole group, an oxadiazole group, an oxatriazole group, a thiazole group, an isothiazole group, a thiadiazole group, a thiatriazole group, a pyrazole group, an imidazole group, a triazole group, a tetrazole group, an azasilole group, a diazasilole group, or a triazasilole group, and
the second ring may be an adamantane group, a norbornane group, a norbornene group, a cyclohexane group, a cyclohexene group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, or a triazine group.
The “fluorinated C1-C60 alkyl group (or fluorinated C1-C20 alkyl group or the like)”, “fluorinated C3-C10 cycloalkyl group”, “fluorinated C1-C10 heterocycloalkyl group”, and “fluorinated phenyl group” as used herein may respectively be a C1-C60 alkyl group (or C1-C20 alkyl group or the like), C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, and a phenyl group, each substituted with at least one fluoro group (—F). Examples of the “fluorinated C1 alkyl group (i.e., a fluorinated methyl group)” may include —CF3, —CF2H, and —CFH2. The “fluorinated C1-C60 alkyl group (or fluorinated C1-C20 alkyl group or the like)”, “fluorinated C3-C10 cycloalkyl group”, “fluorinated C1-C10 heterocycloalkyl group”, or “fluorinated phenyl group” may respectively be: i) a fully fluorinated C1-C60 alkyl group (or fully fluorinated C1-C20 alkyl group or the like), fully fluorinated C3-C10 cycloalkyl group, fully fluorinated C1-C10 heterocycloalkyl group, or fully fluorinated phenyl group, in which all hydrogen atoms are substituted with fluoro groups; or ii) a partially fluorinated C1-C60 alkyl group (or partially fluorinated C1-C20 alkyl group or the like), partially fluorinated C3-C10 cycloalkyl group, partially fluorinated C1-C10 heterocycloalkyl group, or partially fluorinated phenyl group, in which some of hydrogen atoms are substituted with fluoro groups.
The “deuterated C1-C60 alkyl group (or deuterated C1-C20 alkyl group or the like)”, “deuterated C3-C10 cycloalkyl group”, “deuterated C1-C10 heterocycloalkyl group”, and “deuterated phenyl group” as used herein may respectively be a C1-C60 alkyl group (or C1-C20 alkyl group or the like), C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, and a phenyl group, each substituted with at least one deuterium. Examples of the “deuterated C1 alkyl group (i.e., a deuterated methyl group)” may include —CD3, —CD2H, and —CDH2. Examples of the “deuterated C3-C10 cycloalkyl group” may include Formula 10-501. The “deuterated C1-C60 alkyl group (or deuterated C1-C20 alkyl group or the like)”, “deuterated C3-C10 cycloalkyl group”, “deuterated C1-C10 heterocycloalkyl group”, or deuterated phenyl group may respectively be: i) a fully deuterated C1-C60 alkyl group (or fully deuterated C1-C20 alkyl group or the like), fully deuterated C3-C10 cycloalkyl group, fully deuterated C1-C10 heterocycloalkyl group, or fully deuterated phenyl group, in which all hydrogens are substituted with deuterium atoms; or ii) a partially deuterated C1-C60 alkyl group (or partially deuterated C1-C20 alkyl group or the like), partially deuterated C3-C10 cycloalkyl group, partially deuterated C1-C10 heterocycloalkyl group, or partially deuterated phenyl group, in which some of hydrogens are substituted with deuterium atoms.
The “(C1-C20 alkyl)‘X’ group” refers to a ‘X’ group substituted with at least one C1-C20 alkyl group. For example, The “(C1-C20 alkyl)C3-C10 cycloalkyl group” as used herein refers to a C3-C10 cycloalkyl group substituted with at least one C1-C20 alkyl group, and the “(C1-C20 alkyl)phenyl group” as used herein refers to a phenyl group substituted with at least one C1-C20 alkyl group. Examples of the (C1 alkyl)phenyl group may include a toluyl group.
In the present specification, “an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluoren-9-one group, and an azadibenzothiophene 5,5-dioxide group” each refer to a hetero ring in which at least one ring-forming carbon atom is substituted with nitrogen atom and respectively having an identical backbone as “an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, and a dibenzothiophene 5,5-dioxide group”.
A substituent of the substituted C5-C30 carbocyclic group, the substituted C1-C30 heterocyclic group, the substituted C1-C60 alkyl group, the substituted C2-C60 alkenyl group, the substituted C2-C60 alkynyl group, the substituted C1-C60 alkoxy group, the substituted C1-C60alkylthio group, the substituted C3-C10 cycloalkyl group, the substituted C1-C10 heterocycloalkyl group, the substituted C3-C10 cycloalkenyl group, the substituted C1-C10 heterocycloalkenyl group, the substituted C6-C60 aryl group, the substituted C7-C60 alkyl aryl group, the substituted C6-C60 aryloxy group, the substituted C6-C60 arylthio group, the substituted C1-C60 heteroaryl group, the substituted C2-C60 alkyl heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may each independently be:
deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group;
a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C7-C60 alkyl aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a C2-C60 alkyl heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q11)(Q12), —Si(Q13)(Q14)(Q15), —B(Q16)(Q17), —P(═O)(Q18)(Q19), —P(Q18)(Q19), or any combination thereof;
a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C7-C60 alkyl aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a C2-C60 alkyl heteroaryl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C7-C60 alkyl aryl group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C1-C60 heteroaryl group, a C2-C60 alkyl heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q21)(Q22), —Si(Q23)(Q24)(Q25), —B(Q26)(Q27), —P(═O)(Q28)(Q29), —P(Q28)(Q29), or any combination thereof;
—N(Q31)(Q32), —Si(Q33)(Q34)(Q35), —B(Q36)(Q37), —P(═O)(Q38)(Q39), or —P(Q38)(Q39); or
any combination thereof.
In the present specification, Q1 to Q9, Q11 to Q19, Q21 to Q29, and Q31 to Q39 may each independently be: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; an amidino group; a hydrazine group; a hydrazone group; a carboxylic acid group or a salt thereof; a sulfonic acid group or a salt thereof; a phosphoric acid group or a salt thereof; a C1-C60 alkyl group unsubstituted or substituted with deuterium, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; a C3-C10 cycloalkyl group; a C1-C10 heterocycloalkyl group; a C3-C10 cycloalkenyl group; a C1-C10 heterocycloalkenyl group; a C6-C60 aryl group unsubstituted or substituted with deuterium, a C1-C60 alkyl group, a C6-C60 aryl group, or any combination thereof; a C6-C60 aryloxy group; a C6-C60 arylthio group; a C1-C60 heteroaryl group; a monovalent non-aromatic condensed polycyclic group; or a monovalent non-aromatic condensed heteropolycyclic group.
Hereinafter, a compound and an organic light-emitting device according to an embodiment will be described in detail with reference to Synthesis Examples and Examples, however, the present disclosure is not limited thereto. The wording “B was used instead of A” used in describing Synthesis Examples means that an amount of B used was identical to an amount of A used based on molar equivalence.
5.7 grams (g) of Intermediate B-1 (0.011 mol, 0.9 equiv.), 6.6 g of Intermediate A-1 (0.012 mol, 1 equiv.), 0.96 g of tetrakis(triphenylphosphine)palladium(0) (0.001 mmol, 0.07 equiv.), and 4.9 g of potassium carbonate (0.036 mol, 3 equiv.) were dissolved in 80 milliliters (mL) of a solvent in which tetrahydrofuran (THF) and distilled water (H2O) were mixed at a volume ratio of 3:1, followed by reflux for 12 hours. The resulting product was cooled to room temperature, and a precipitate was filtered to obtain a filtrate. The obtained filtrate was washed with EA (ethyl acetate) and H2O, the organic layer was concentrated and purified by column chromatography with gradient elution (while increasing a rate of EA/hexane to between 8% and 15%), and recrystallization was performed using MC (methylene chloride)/MeOH to obtain 4.8 g of Ligand C-1 (having a purity of 99% or higher). The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C63H63N3O: m/z 877.4971, Found: 877.4975
4.9 g of ligand C-1 (5.55 mmol) and 2.76 g of K2PtCl4 (6.65 mmol, 1.2 equiv.) were dissolved in 110 mL of a mixture of 100 mL of AcOH (acetic acid) and 10 mL of H2O, followed by reflux for 16 hours. The resulting product was cooled to room temperature, and a precipitate was filtered to obtain a filtrate. The obtained filtrate was extracted with methylene chloride (MC) and washed with H2O, the organic layer was concentrated, and the obtained residue was purified by column chromatography to obtain 2.2 g of Compound 1 (yield: 37%). The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C63H61N3OPt: m/z 1070.4462, Found: 1070.4464
3.4 grams (g) of Intermediate B-3 (0.006 mol, 0.9 equiv.), 4.0 g of Intermediate A-3 (0.006 mol, 1 equiv.), 0.53 g of tetrakis(triphenylphosphine)palladium(0) (0.001 mmol, 0.07 equiv.), and 2.7 g of potassium carbonate (0.020 mol, 3 equiv.) were dissolved in 80 milliliters (mL) of a solvent in which tetrahydrofuran (THF) and distilled water (H2O) were mixed at a volume ratio of 3:1, followed by reflux for 12 hours. The resulting product was cooled to room temperature, and a precipitate was filtered to obtain a filtrate. The obtained filtrate was washed with EA and H2O, the organic layer was concentrated, and the resulting residue was purified by column chromatography with gradient elution (while increasing a rate of EA/hexane to between 8% and 15%), and recrystallization was performed using MC/MeOH to obtain 4.5 g of Ligand C-3 (having a purity of 99% or higher). The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C70H73D2N3O: m/z 975.6036, Found: 975.6039
4.5 g of ligand C-3 (5.25 mmol) and 2.61 g of K2PtCl4 (6.30 mmol, 1.2 equiv.) were dissolved in 100 mL of a mixture of 100 mL of AcOH and 10 mL of H2O, followed by reflux for 16 hours. The resulting product was cooled to room temperature, and a precipitate was filtered to obtain a filtrate. The obtained filtrate was extracted with MC and washed with H2O, the organic layer was concentrated to obtain a residue, and the obtained residue was purified by column chromatography (MC 40%, Hexane 60%) to obtain 1.84 g of Compound 3 (yield: 30%). The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C70H71D2N3OPt: m/z 1168.5527, Found: 1168.5528
3.0 g of ligand C-177 (having a purity of 98% or higher) was obtained in substantially the same manner as in Synthesis of ligand C-3 in Synthesis Example 2, except that Intermediate A-177 and Intermediate B-177 were used instead of Intermediate A-3 and Intermediate B-3, respectively. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C66H65D2N30: m/z 919.5410, Found: 919.5412
1.2 g of Compound 177 (yield: 34%) was obtained in substantially the same manner as in Synthesis of Compound 3 in Synthesis Example 2, except that ligand C-177 was used instead of ligand C-3. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C66H63D2N3OPt: m/z 1112.4901, Found: 1112.4903
3.2 g of ligand C-187 (having a purity of 98% or higher) was obtained in substantially the same manner as in Synthesis of ligand C-3 in Synthesis Example 2, except that Intermediate B-187 was used instead of Intermediate B-3. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C64H73N3O: m/z 899.5754, Found: 899.5757
1.67 g of Compound 187 (yield: 43%) was obtained in substantially the same manner as in Synthesis of Compound 3 in Synthesis Example 2, except that ligand C-187 was used instead of ligand C-3. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C64H71N3OPt: m/z 1092.5245, Found: 1092.5243 Synthesis Example 5 (Compound 218)
2.8 g of ligand C-218 (having a purity of 97% or higher) was obtained in substantially the same manner as in Synthesis of ligand C-3 in Synthesis Example 2, except that Intermediate B-1 was used instead of Intermediate B-3. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C67H71N3O: m/z 933.5597, Found: 933.5599
1.39 g of Compound 218 (yield: 41%) was obtained in substantially the same manner as in Synthesis of Compound 3 in Synthesis Example 2, except that ligand C-218 was used instead of ligand C-3. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C67H69N3OPt: m/z 1126.5088, Found: 1126.5087
3.0 g of ligand C-246 (having a purity of 97% or higher) was obtained in substantially the same manner as in Synthesis of ligand C-3 in Synthesis Example 2, except that Intermediate B-246 was used instead of Intermediate B-3. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C64H71N3O: m/z 897.5597, Found: 897.5599
1.42 g of Compound 246 (yield: 39%) was obtained in substantially the same manner as in Synthesis of Compound 3 in Synthesis Example 2, except that ligand C-246 was used instead of ligand C-3. The resulting compound was identified by using mass spectroscopy and HPLC analysis.
HRMS(MALDI) calcd for C64H69N3OPt: m/z 1090.5088, Found: 1090.5087
The singlet (S1) energy level and the triplet (T1) energy level of the organometallic Compounds 1, 3, 177, 187, 218 and 246 and Compounds A, B, and C were evaluated by using a Gaussian program according to a density functional theory (DFT) method (structure optimization was performed at a degree of B3LYP, and 6-31 G(d,p)). The results thereof are shown in Table 1.
As shown in Table 1, Compounds 1, 3, 177, 187, 218 and 246 were found to have ΔST in a range of 0.1 eV to 0.2 eV.
mCP and Compound 1 were co-deposited on a quartz substrate at a weight ratio of 92:8 in a vacuum pressure of 10-7 torr to form a film having a thickness of 40 nm. Then, a glass substrate for encapsulation was attached on the film to encapsulate the film.
The photoluminescence (PL) intensity according to angle of the film was measured by using a Luxol-OLED/analyzer LOA-100 (available from CoCoLink) from −150° to +150°. Then, the horizontal orientation ratio of Compound 1 was calculated by using a fitting program of the analyzer. The results thereof are shown in Table 2. The same process was performed on the compounds shown in Table 2. The results thereof are also shown in Table 2.
Referring to the results of Table 2, the horizontal orientation ratios of Compounds 1, 3, 177, 187, 218 and 246 were found to be higher than the horizontal orientation ratios of Compounds A, B, and C.
Thermal analysis (N2 atmosphere, a temperature range: from room temperature to 800° C. (10° C./min)-TGA, from room temperature to 400° C.-DSC, Pan Type: Pt Pan in disposable Al Pan (TGA) and disposable Al pan (DSC)) was performed on Compounds 1, 3, 177, 187, 218 and 246 by using thermo gravimetric analysis (TGA) and differential scanning calorimetry (DSC). The evaluation results are shown in Table 3.
Referring to the results of Table 3, Compounds 1, 177, 187, 218 and 246 were each found to have a relatively low sublimation temperature. Thus, a thin film having excellent performance may be prepared by using above compounds.
A glass substrate, on which ITO is patterned as an anode, was cut to a size of 50 millimeters (mm)×50 mm×0.5 mm, sonicated in isopropyl alcohol and water for 5 minutes each, and cleaned by exposure to ultraviolet rays and ozone for 30 minutes. Subsequently, the glass substrate was mounted on a vacuum-deposition device.
HT3 and F6-TCNNQ were vacuum-co-deposited at a weight ratio of 98:2 on the anode to form a hole injection layer having a thickness of 100 Å. HT3 was vacuum-deposited on the hole injection layer to form a hole transport layer having a thickness of 1,350 Å. Then, H-H1 was vacuum-deposited on the hole transport layer to form an electron blocking layer having a thickness of 300 Å.
Subsequently, H-H1 and H-E43 (as hosts) and Compound 1 (as a dopant) were co-deposited on the electron blocking layer at a weight ratio of 47.5:47.5:5 to form an emission layer having a thickness of 400 Å.
ET3 and ET-D1 were co-deposited at a volume ratio of 50:50 on the emission layer to form an electron transport layer having a thickness of 350 Å, ET-D1 was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 Å, and Al was vacuum-deposited on the electron injection layer to form a cathode having a thickness of 1,000 Å, thereby completing the manufacture of an organic light-emitting device.
Organic light-emitting devices were manufactured in substantially the same manner as in Example 1, except that the compounds listed in Table 4 were used instead of Compound 1 as a dopant in the formation of an emission layer.
A current voltmeter (Keithley 2400) and a luminescence meter (Minolta Cs-1000A) were used on the organic light-emitting devices of Examples 1 to 6 and Comparative Examples A, B, and C to measure the driving voltage, luminescence efficiency (cd/A), and a quantum emission yield (%). The results thereof are shown in Table 4. The luminescence efficiency is shown in a relative value.
Referring to the results of Table 4, the organic light-emitting devices of Examples 1 to 6 were found to have excellent driving voltage, excellent luminescence efficiency, and improved quantum emission yield, as compared with the organic light-emitting devices of Comparative Examples A, B, and C.
As apparent from the foregoing description, the organometallic compound has excellent electrical characteristics and thermal stability. Accordingly, an organic light-emitting device including the organometallic compound may have an improved driving voltage, improved luminescence efficiency, and improved external quantum emission yield. Therefore, a high-quality electronic apparatus may be realized by using the organic light-emitting device.
It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments. While one or more embodiments have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope as defined by the following claims.
Number | Date | Country | Kind |
---|---|---|---|
10-2021-0046891 | Apr 2020 | KR | national |
10-2020-0045374 | Apr 2020 | KR | national |